Department of Thoracic Surgery, Jilin Provincial People's Hospital, Chaoyang, Changchun, Jilin, China.
Anticancer Drugs. 2023 Nov 1;34(10):1151-1161. doi: 10.1097/CAD.0000000000001505. Epub 2023 Jan 24.
Chemoresistance is the leading cause of poor outcomes of non-small cell lung cancer (NSCLC). Circular RNA (circRNA) plays a vital role in NSCLC resistance progression. Our study aimed to uncover the role of circRNA PDZ domain containing 8 (circ_0091537) in NSCLC with gefitinib resistance. The expression of circ_0091537, microRNA-520h (miR-520h), and Yes-associated protein 1 (YAP1) mRNA were detected using quantitative real-time PCR. Cell viability and cell proliferation were assessed by MTT assay and colony formation assay. Colony formation ability was detected by colony formation assay. Cell cycle distribution and cell apoptosis were determined by flow cytometry assay. Cell migration and cell invasion were detected by transwell assay. The potential relationship between miR-520h and circ_0091537 or YAP1 was verified by dual-luciferase reporter assay. Tumor formation assay in nude mice was performed to test the role of circ_0091537 in vivo . Circ_0091537 and YAP1 were upregulated, while miR-520h was downregulated in gefitinib-resistant NSCLC cells. Circ_0091537 knockdown inhibited gefitinib resistance in NSCLC cells and then inhibited NSCLC cell growth, migration, and invasion. MiR-520h was a target of circ_0091537, and miR-520h inhibition reversed the effects of circ_0091537 knockdown. Moreover, YAP1 was a target of miR-520h, and circ_0091537 competitively combined with miR-520h to enrich YAP1 expression. MiR-520h restoration impaired gefitinib resistance and suppressed NSCLC cell proliferation, migration, and invasion by repressing YAP1. Circ_0091537 overexpression weakened gefitinib sensitivity in vivo to promote tumor growth. Circ_0091537 strengthens gefitinib chemoresistance to promote NSCLC progression by mediating the miR-520h/YAP1 network, suggesting that circ_0091537 may be a key indicator in resistance to treatment of NSCLC.
化学耐药性是非小细胞肺癌(NSCLC)不良预后的主要原因。环状 RNA(circRNA)在 NSCLC 耐药进展中发挥着重要作用。我们的研究旨在揭示 PDZ 结构域包含 8 号环状 RNA(circ_0091537)在吉非替尼耐药的 NSCLC 中的作用。使用实时定量 PCR 检测 circ_0091537、miR-520h(miR-520h)和 Yes 相关蛋白 1(YAP1)mRNA 的表达。通过 MTT 测定法和集落形成测定法评估细胞活力和细胞增殖。通过集落形成测定法检测集落形成能力。通过流式细胞术测定法检测细胞周期分布和细胞凋亡。通过 Transwell 测定法检测细胞迁移和细胞侵袭。通过双荧光素酶报告基因测定法验证 miR-520h 与 circ_0091537 或 YAP1 之间的潜在关系。裸鼠肿瘤形成实验检测 circ_0091537 在体内的作用。吉非替尼耐药 NSCLC 细胞中 circ_0091537 和 YAP1 上调,而 miR-520h 下调。circ_0091537 敲低抑制 NSCLC 细胞的吉非替尼耐药,并抑制 NSCLC 细胞生长、迁移和侵袭。miR-520h 是 circ_0091537 的靶标,miR-520h 抑制逆转了 circ_0091537 敲低的作用。此外,YAP1 是 miR-520h 的靶标,circ_0091537 竞争性结合 miR-520h 以富集 YAP1 表达。miR-520h 的恢复通过抑制 YAP1 损害吉非替尼耐药并抑制 NSCLC 细胞增殖、迁移和侵袭。circ_0091537 的过表达减弱了体内吉非替尼的敏感性,从而促进肿瘤生长。circ_0091537 通过调节 miR-520h/YAP1 网络增强吉非替尼化疗耐药性,促进 NSCLC 进展,表明 circ_0091537 可能是 NSCLC 治疗耐药的关键指标。